NO923911L - Nye 17beta-substituerte aza-androstan derivater - Google Patents

Nye 17beta-substituerte aza-androstan derivater

Info

Publication number
NO923911L
NO923911L NO92923911A NO923911A NO923911L NO 923911 L NO923911 L NO 923911L NO 92923911 A NO92923911 A NO 92923911A NO 923911 A NO923911 A NO 923911A NO 923911 L NO923911 L NO 923911L
Authority
NO
Norway
Prior art keywords
phe
formula
17beta
group
new
Prior art date
Application number
NO92923911A
Other languages
English (en)
Other versions
NO923911D0 (no
Inventor
Michel Biollaz
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO923911D0 publication Critical patent/NO923911D0/no
Publication of NO923911L publication Critical patent/NO923911L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelser med formelen. hvor karbonatomene 1 og 2 er bundet med en enkelt eller dobbeltbindlng, Rer hydrogen, metyl eller etyl, og A er en gruppe med formelen -N(-R)-X- hvor Rer hydrogen eller C-Calkyl og X er1-lkylen eller CT-Csykloalkyliden; en gruppe med formelen -N(-R)-Y-Phe- hvor P,2 er som definert over, Y er en direkte binding eller C-C-alkylen og Phe er et ikke-substltuert eller substituert fenylenradikal; en gruppe med formelen -0-X- hvor X er som definert over eller en gruppe -O-Y-Phe hvor Y og Phe er som definert over, er hemmere av 5a-reduktase og kan derfor bli brukt for terapeutisk behandling av det humane og animalske legeme.
NO92923911A 1991-10-09 1992-10-08 Nye 17beta-substituerte aza-androstan derivater NO923911L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH297891 1991-10-09

Publications (2)

Publication Number Publication Date
NO923911D0 NO923911D0 (no) 1992-10-08
NO923911L true NO923911L (no) 1993-04-13

Family

ID=4245915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92923911A NO923911L (no) 1991-10-09 1992-10-08 Nye 17beta-substituerte aza-androstan derivater

Country Status (19)

Country Link
US (2) US5304562A (no)
EP (1) EP0538192B1 (no)
JP (1) JPH05213989A (no)
KR (1) KR930007969A (no)
AT (1) ATE152121T1 (no)
AU (1) AU657579B2 (no)
CA (1) CA2080054A1 (no)
DE (1) DE59208383D1 (no)
DK (1) DK0538192T3 (no)
ES (1) ES2101073T3 (no)
FI (1) FI924529A (no)
GR (1) GR3024013T3 (no)
HU (1) HUT62600A (no)
IL (1) IL103361A (no)
MX (1) MX9205792A (no)
NO (1) NO923911L (no)
NZ (1) NZ244640A (no)
TW (1) TW263513B (no)
ZA (1) ZA927747B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
CZ283894A3 (en) * 1992-05-20 1995-09-13 Merck & Co Inc 7beta-substituted 4-aza-5alpha-cholestanones, their use for the preparation of pharmaceutical preparations and pharmaceutical compositions containing thereof
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
AU5323694A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
AU707324B2 (en) * 1995-09-15 1999-07-08 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0271219B1 (en) * 1986-11-20 1992-07-29 Merck & Co. Inc. Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives

Also Published As

Publication number Publication date
DK0538192T3 (da) 1997-05-20
US5378710A (en) 1995-01-03
US5304562A (en) 1994-04-19
KR930007969A (ko) 1993-05-20
FI924529A (fi) 1993-04-10
MX9205792A (es) 1993-08-01
JPH05213989A (ja) 1993-08-24
AU2626192A (en) 1993-04-22
ES2101073T3 (es) 1997-07-01
IL103361A (en) 1997-06-10
TW263513B (no) 1995-11-21
AU657579B2 (en) 1995-03-16
NZ244640A (en) 1994-12-22
DE59208383D1 (de) 1997-05-28
FI924529A0 (fi) 1992-10-07
HU9203189D0 (en) 1992-12-28
HUT62600A (en) 1993-05-28
ATE152121T1 (de) 1997-05-15
IL103361A0 (en) 1993-03-15
NO923911D0 (no) 1992-10-08
EP0538192A1 (de) 1993-04-21
CA2080054A1 (en) 1993-04-10
EP0538192B1 (de) 1997-04-23
GR3024013T3 (en) 1997-10-31
ZA927747B (en) 1993-04-13

Similar Documents

Publication Publication Date Title
NO923911L (no) Nye 17beta-substituerte aza-androstan derivater
DE3789967T2 (de) Anwendung von monoaminakridinen bei mangelerscheinungen des cholinergen nervensystems.
HUP0002495A1 (hu) VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE9100342D0 (sv) Novel steroid esters
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
NO167088C (no) Nye 5-alkoxy-2,4 diaminoalkylbenzener saavel som haarfarvemiddel med 5-alkoxy-2,4-diamino-alkylbenzen.
NO940523D0 (no) Nye pyrazin-derivater
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
NO173057C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzanilidderivater
ATE139441T1 (de) Verwendung von 2-iminothiazolidin-4-onderivaten als neuartige arzneimittelwirkstoffe
ES2157498T3 (es) Derivados de triazol o sus sales.
ATE147755T1 (de) Dipeptidderivate und diese als aktive bestandteile enthaltendes prophylaktisches oder therapeutisches mittel gegen knochenkrankheiten
NO164170C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-benzhydryl-4-cinnamyl-piperazinderivater.
DE69902821T2 (de) 4'-substituierte-4',5'-dihydropsoralene und deren therapeutische verwendung
HUP0003215A2 (hu) Farnezil-protein-transzferáz új fenil-szubsztituált triciklusos inhibitorai
NO944476L (no) Tetrahydro - og perhydro-isokinolinderivater og terapeutiske midler inneholdende dem